ZeroStack (ZSTK)
Stakes 0G tokens and distributes pharmaceuticals through its German Phatebo business.
Something off on this page? Send us feedback.
Combines 0G token staking, which generates validation rewards, with Phatebo's pharmaceutical distribution business. The asset base is concentrated in the 0G network, while commercial operations depend on product inventory financing.
Pairs a 0G token treasury and staking operation with Phatebo, a German pharmaceutical wholesaler. Phatebo imports and exports pharmaceutical and medical products, distributing primarily across Europe and also in Asia, Latin America, and North America; its sales form the commercial revenue base.
Earns digital-asset revenue from 0G validation rewards through a third-party validator, while maintaining control of its staked tokens. Management allocates capital between the two segments and may finance token purchases through equity or debt.
Depends on the 0G network's adoption, staking rules, limited custody and trading access, and evolving token, investment-company, and AI regulation. Phatebo's ability to fulfill its orders also depends on inventory financing.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.0M · Total debt $2.8M · Total assets $25.2M · Shareholders' equity $13.8M
- Revenue
- $13.7M
- Operating income
- −$2.1M
- Net income
- −$24.6M
No dividends on record.
| Institutions | 5.86% | 61.3K shares | |
|---|---|---|---|
| 11 holders · as of Jun 30, 2026 | |||
| Insiders | 1,013.04% | 10.60M shares | |
| 5 holders · as of Jul 20, 2026 | |||
| Adds to | 1,018.90% | ||
1.05M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 1,018.90%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Daniel Reis-FariaInsiderdirector, officer: CEO | 569.29% | 5.95M | filed Jul 20, 2026 |
Michael HeinrichInsiderdirector, officer: Executive Chairman | 440.59% | 4.61M | filed Jul 20, 2026 |
Vanguard Capital Management LLCInstitution | 2.43% | 25,440 | as of Jun 30, 2026 |
Clifford StarkeInsiderdirector, officer: CEO | 2.22% | 23,252 | filed Dec 17, 2024 |
Geode Capital Management, LLCInstitution | 2.01% | 20,994 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 19, 2026 | Rudy Rong | officer: President | −1,000 | $7.57 |
| Jul 20, 2026 | Michael Heinrich | director, officer: Executive Chairman | +4,608,575 | $0.7549 |
| Oct 9, 2025 | Daniel Reis-Faria | director, officer: CEO | +5,954,743 | $0.0001 |
- Cencora
European pharmaceutical distribution overlap in supplier and pharmacy channels.
- DeFi Development
Solana treasury and validator model overlaps with 0G staking.
- Sharplink
Ethereum treasury and staking alternative for digital-asset investors.
- Strategy
Large public Bitcoin treasury benchmark for digital-asset capital.
- Interactive Strength
AI-token treasury alternative tied to Fetch.ai's agent ecosystem.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| ZeroStack | $4.02 | −6.94% | $4.5M | — | — | 0.1 | −7.7% |
| Cencora | $317.15 | +0.21% | $61.58B | 23.5 | 16.3 | 0.2 | +5.1% |
| DeFi Development | $6.05 | −7.14% | $196.1M | — | — | 13.0 | +66.9% |
| Sharplink | $10.22 | +2.40% | $1.97B | — | 91.5 | 39.2 | +1,553.3% |
| Strategy | $168.84 | +0.20% | $55.74B | — | 5.1 | 111.9 | +6.9% |
| Interactive Strength | $2.96 | +5.71% | $1.4M | — | — | 0.1 | +441.4% |
| Median | 23.5 | 16.3 | 13.0 | +66.9% |